Rapport Therapeutics (NASDAQ:RAPP) Hits New 12-Month Low – What’s Next?

Rapport Therapeutics (NASDAQ:RAPP) shares reached a new 52-week low during trading on Wednesday . The stock traded as low as $16.51 and last traded at $16.67, with a volume of 22375 shares traded. The stock had previously closed at $17.79.

Rapport Therapeutics Stock Down 11.3 %

The business’s 50 day moving average is $20.66.

Hedge Funds Weigh In On Rapport Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. TD Asset Management Inc acquired a new stake in shares of Rapport Therapeutics in the 2nd quarter valued at approximately $2,361,000. Johnson & Johnson purchased a new stake in shares of Rapport Therapeutics in the 2nd quarter worth about $58,105,000. Sofinnova Investments Inc. purchased a new position in shares of Rapport Therapeutics during the 2nd quarter worth approximately $45,393,000. Davidson Kempner Capital Management LP purchased a new position in Rapport Therapeutics during the second quarter worth $229,000. Finally, ARCH Venture Management LLC acquired a new position in Rapport Therapeutics in the 2nd quarter valued at about $86,730,000.

Rapport Therapeutics Company Profile

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.